Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Fluorouracil 67Leucovorin 61Oxaliplatin 49Irinotecan 31Capecitabine 23Cetuximab 22Bevacizumab 20Folfox protocol 13Radiotherapy 12Chemotherapy, Adjuvant 11Neoadjuvant Therapy 10Erlotinib Hydrochloride 7dehydroftorafur 5Trastuzumab 5Radiation 5Melphalan 5Magnetic Resonance Spectroscopy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5sargramostim 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Gene Expression Profiling 4Gefitinib 4Floxuridine 4Biopsy 4aldesleukin 3Sorafenib 3Semaxinib 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rectal Neoplasms × Pyridoxine × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡